Pretzel Therapeutics, Inc. has received authorisation from the United Kingdom’s Medicines and Healthcare products Regulatory Agency to advance PX578 into clinical testing in patients with POLG-mediated primary mitochondrial disease. Announced on October 30, 2026, the decision permits the company to proceed with the authorised UK clinical trial programme for its investigational small-molecule POLG activator, building on US regulatory clearance and a completed Phase 1 healthy volunteer study.
The milestone supports Pretzel Therapeutics’ planned Phase 2 POLARIS trial, which will evaluate PX578 in adults with a rare genetic disorder associated with mitochondrial DNA depletion and impaired cellular energy production. The company expects to initiate the study before the end of 2026, with a randomised, double-blind, placebo-controlled design examining safety, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy. Its broader objective is to determine whether directly enhancing POLG activity can address a fundamental biological defect rather than only managing individual disease symptoms.
However, the UK authorisation is permission to conduct a clinical investigation, not marketing approval for PX578. The company has not yet disclosed efficacy results from patients with POLG disease, and the announcement does not confirm that POLARIS has begun dosing participants. The programme therefore remains at an important but early clinical stage, where its disease-modifying potential must still be demonstrated.
Why is UK authorisation an important regulatory milestone for Pretzel Therapeutics’ PX578 programme?
The Medicines and Healthcare products Regulatory Agency has authorised the company’s clinical trial application for PX578, allowing the proposed investigation to proceed in the United Kingdom under the applicable regulatory requirements. The decision follows clearance of an Investigational New Drug application by the United States Food and Drug Administration in August 2026. It also follows the FDA’s granting of Fast Track designation in September.
These developments establish regulatory pathways for advancing the programme in two major clinical research jurisdictions. The FDA IND clearance permits clinical investigation under the authorised US programme, while the UK decision supports the corresponding clinical development activities in that country. Neither decision establishes that the medicine has demonstrated efficacy in patients.
Fast Track designation has a separate function. The FDA uses the programme to facilitate development and potentially accelerate review of medicines addressing serious conditions with unmet medical needs. It can support increased regulatory interaction and provide access to certain review mechanisms when relevant requirements are satisfied.
However, Fast Track designation does not shorten every study automatically, remove the need for adequate clinical evidence or guarantee marketing approval. Pretzel Therapeutics must still demonstrate an acceptable benefit-risk profile through appropriate development and regulatory submissions.
Jay Parrish, chairman and chief executive officer of Pretzel Therapeutics, has positioned the UK authorisation as an important development milestone for a potential treatment targeting the underlying mitochondrial dysfunction. Management is now concentrating on executing the planned POLARIS study. The immediate test will be whether regulatory readiness translates into successful patient enrolment and clinical data generation.
How does POLG-mediated mitochondrial disease disrupt the body’s ability to produce energy?
Mitochondria are specialised structures within cells that play a central role in producing energy through oxidative phosphorylation. Although most genetic information is stored in the cell nucleus, mitochondria also contain their own DNA. This mitochondrial DNA encodes essential components involved in cellular energy production.
The POLG gene provides instructions for producing the catalytic component of DNA polymerase gamma, the enzyme responsible for replicating and maintaining mitochondrial DNA. Pathogenic changes in POLG can impair this process, reducing the amount or integrity of mitochondrial DNA available within cells. The resulting dysfunction can disrupt energy production and affect tissues with particularly high metabolic requirements.
The brain, skeletal muscles, peripheral nerves and liver are among the tissues that can be substantially affected. Patients may develop neurological symptoms, muscle weakness, impaired coordination, seizures and other manifestations depending on the underlying genetic changes and disease course. The severity can vary widely, even among individuals classified within the broader POLG-related disease spectrum.
POLG-related conditions are often discussed within the category of mitochondrial DNA depletion syndromes. However, mitochondrial DNA depletion is not the only biological abnormality associated with POLG variants, and some patients may also experience mitochondrial DNA instability or multiple deletions. The precise mechanism and clinical presentation can differ according to the genetic variant and disease phenotype.
This variability creates a challenge for therapeutic development. A medicine intended to increase POLG activity may affect different patients differently depending on their residual enzyme function and the nature of the genetic defect. The clinical usefulness of PX578 will therefore depend partly on whether the intended mechanism applies across the population selected for treatment.
How is PX578 designed to activate mitochondrial DNA polymerase and increase mitochondrial DNA levels?
PX578 is described by Pretzel Therapeutics as a first-in-class, central nervous system-penetrant small-molecule activator of POLG. Rather than replacing the defective gene or introducing additional mitochondrial DNA directly, the compound is intended to improve the activity of the existing mitochondrial DNA replication machinery. The proposed objective is to increase mitochondrial DNA levels and support more effective cellular energy production.
The biological rationale centres on the relationship between POLG function and mitochondrial DNA maintenance. If a pathogenic variant reduces the enzyme’s ability to replicate mitochondrial DNA, a compound that improves relevant enzyme activity could potentially increase the amount of mitochondrial genetic material retained within affected cells. However, the extent of benefit would depend on the residual function of the mutated enzyme and other aspects of mitochondrial biology.
Pretzel Therapeutics has identified polymerase processivity as an important component of the proposed mechanism. Processivity describes the ability of an enzyme to continue synthesising DNA during a replication event without repeatedly disengaging from its template. Improving this characteristic could theoretically support more effective mitochondrial DNA replication in selected disease settings.
The company says PX578 has demonstrated biological activity across several POLG mutation models during preclinical research. However, those findings cannot establish that the same mechanism will produce clinically meaningful benefits across the full range of human POLG variants. Some disease-associated mutations may have different functional consequences that influence responsiveness.
The drug’s reported ability to penetrate the central nervous system is another potentially relevant characteristic because neurological disease contributes substantially to the burden of POLG disorders. Nevertheless, central nervous system penetration must be considered alongside actual exposure, tissue-level biological activity and safety. Reaching the relevant tissue is necessary but not sufficient to establish therapeutic benefit.
What did the 2026 preclinical studies demonstrate about mitochondrial DNA restoration with PX578?
Pretzel Therapeutics presented additional PX578 findings at the Muscular Dystrophy Association Clinical and Scientific Conference in March 2026. The research included laboratory and animal models intended to examine whether the compound could increase mitochondrial DNA and improve biological functions associated with cellular energy production. The company reported positive findings across several experimental systems.
According to Pretzel Therapeutics, PX578 increased mitochondrial DNA levels and improved cellular respiration and energy production in the evaluated models. Selected experiments also demonstrated improvements in survival and markers associated with liver health. These findings provide mechanistic support for continued clinical investigation.
The company further reported that PX578 demonstrated activity across all POLG mutations it had evaluated at that stage. The tested variants included four common mutations that Pretzel Therapeutics said are found in approximately 70% of affected patients. This suggests a potentially broad pharmacological effect within the evaluated mutation panel.
However, activity across several preclinical mutations does not establish that all individuals with POLG disease will respond. Laboratory systems may not reproduce the full complexity of human disease, including differences in mitochondrial DNA depletion, neurological damage and organ involvement. The significance of the findings will depend on whether similar biological effects are observed at tolerable exposure levels in patients.
The preclinical survival observations also require careful separation from human outcomes. Improved survival in an experimental model does not establish that PX578 prolongs life in people with POLG disease. The planned clinical programme is intended to begin evaluating whether the laboratory findings have meaningful therapeutic relevance.
Why does the completed Phase 1 healthy volunteer study matter before POLARIS begins enrolling patients?
Pretzel Therapeutics initiated a Phase 1 clinical study of PX578 in healthy volunteers during 2025. The investigation was designed to evaluate safety, tolerability and pharmacokinetics after single and multiple ascending doses. The programme included an assessment of the effect of food on drug exposure.
The company confirmed in August 2026 that the healthy volunteer study had been completed successfully and met its objectives. This provided an initial human safety and exposure foundation for seeking permission to evaluate PX578 in patients with POLG-mediated disease. The subsequent US IND clearance and UK trial authorisation reflect progress towards that next development stage.
However, Pretzel Therapeutics has not disclosed a full numerical Phase 1 dataset in the October announcement. Detailed adverse-event rates, dose-exposure relationships and pharmacokinetic measurements were not provided. The company’s description of successful completion therefore cannot be used to independently quantify the medicine’s tolerability or predict the optimal dose for affected patients.
Healthy volunteer research also has inherent limitations when evaluating medicines intended for people with genetic mitochondrial disorders. Patients may have impaired energy metabolism, neurological complications or liver dysfunction that are not present in healthy participants. These characteristics could influence both drug exposure and treatment-related risks.
The Phase 1 results are therefore relevant primarily to initial safety and pharmacology. They do not demonstrate that activating POLG improves mitochondrial DNA levels in affected patients or changes the course of the disease. Those questions require clinical investigation in the intended population.
What will the Phase 2 POLARIS study evaluate in adults with POLG-mediated primary mitochondrial disease?
POLARIS, short for POLG Activation and Recovery In Subjects, is the planned Phase 2 investigation of PX578 in adults with POLG-mediated mitochondrial disease. The study is designed as a randomised, double-blind, placebo-controlled trial. Its objectives include assessing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy.
The controlled design is particularly important because POLG-related disorders can progress at different rates and produce variable symptoms. A comparison with placebo may help determine whether observed changes are attributable to treatment rather than background variability or other clinical factors. Blinding can also reduce bias when evaluating outcomes involving physical function or patient-reported symptoms.
Pharmacodynamic assessments will be relevant because they examine whether the medicine produces biological effects consistent with its proposed mechanism. Potential measures may involve mitochondrial function or related biomarkers, although the October announcement does not identify the complete endpoint framework. Specific assumptions about the study’s primary clinical endpoint would therefore be premature.
The ability to connect biological activity with meaningful patient outcomes will be central to the programme. Increased mitochondrial DNA levels could support the mechanism of action, but the more consequential question is whether such changes improve neurological or muscular function or slow further deterioration. Demonstrating that relationship may require sufficient treatment duration and appropriate clinical measurements.
Pretzel Therapeutics expects to initiate POLARIS before the end of 2026. However, the company has not provided a confirmed first-patient dosing date, enrolment target or anticipated topline readout in its October announcement. Those details will be important for assessing the pace and scope of development.
Why will genetic differences and age of disease onset complicate the assessment of PX578 efficacy?
POLG-related disorders encompass a broad group of clinical presentations extending from early childhood to later adult life. The disease can involve different combinations of liver dysfunction, neurological symptoms, muscle weakness and progressive impairment. Age of onset is often associated with important differences in severity and prognosis.
Childhood-onset forms can be particularly severe, with seizures, liver involvement and developmental regression. Juvenile and adult-onset disease may include ataxia, peripheral neuropathy, seizures and progressive external ophthalmoplegia. Later-onset presentations can involve drooping eyelids, impaired eye movement and muscle weakness.
These differences create challenges for selecting a representative clinical trial population. Patients may have different baseline levels of disability and distinct patterns of progression, making a single functional measure insufficient to capture every relevant outcome. Genetic variants may also influence how much residual POLG activity is available for pharmacological enhancement.
POLARIS is initially focused on adults rather than the full age spectrum. This may help reduce some clinical variability, but adult patients can still differ substantially in symptoms, disease duration and progression. The study’s eligibility criteria and endpoint selection will therefore be essential to interpreting any observed treatment effect.
The distinction between stabilisation and recovery will also matter. Preventing further deterioration could be clinically valuable in a progressive disorder, even if previously damaged tissue does not regain full function. However, demonstrating disease stabilisation requires an adequate comparator and sufficient follow-up to distinguish treatment benefit from naturally slower progression.
How does POLG disease’s lack of approved disease-modifying treatments influence clinical development?
There are currently no approved medicines specifically demonstrated to modify the underlying course of POLG-mediated primary mitochondrial disease. Management generally focuses on treating symptoms, reducing complications and preserving function through multidisciplinary care. Neurological, metabolic, rehabilitation and other specialist services may all be required depending on disease manifestations.
Epilepsy management is particularly challenging in some affected patients. POLG-related disorders can involve difficult-to-control seizures, while certain medicines create additional risks. Valproic acid and related preparations are generally avoided because of the potential to precipitate or worsen severe liver dysfunction.
Other clinical priorities may include nutritional support, respiratory assessment, rehabilitation and monitoring for liver or neurological complications. Supportive care can remain essential even when an investigational disease-modifying therapy is being evaluated. PX578 would not automatically replace these measures if it ultimately demonstrates efficacy.
The absence of approved disease-modifying treatments creates an important medical rationale for investigating approaches directed at mitochondrial DNA replication. However, unmet need alone does not establish that a treatment should receive approval. Regulators must still evaluate whether the available evidence supports a favourable benefit-risk profile.
The disease’s rarity may also influence clinical trial design and patient recruitment. Pretzel Therapeutics will need to identify eligible adults, confirm relevant genetic diagnoses and coordinate assessments across specialist centres. International clinical development may help address some of these challenges, but the available patient population remains limited.
Could POLG activation create opportunities beyond inherited mitochondrial DNA depletion disorders?
Pretzel Therapeutics is developing PX578 as part of a broader strategy focused on restoring cellular energy metabolism. Its initial clinical indication is POLG-mediated primary mitochondrial disease, where dysfunction of the mitochondrial DNA replication enzyme provides a direct mechanistic rationale. The company has also identified a wider opportunity involving disorders characterised by impaired mitochondrial function.
Mitochondrial abnormalities are associated with several neurological, muscular and metabolic conditions. However, their role varies substantially across diseases, and the presence of mitochondrial dysfunction does not automatically establish that POLG activation will be beneficial. Some conditions may involve defects in energy production that are not primarily driven by insufficient mitochondrial DNA replication.
The company has conducted research into the potential relevance of POLG activation in broader neurodegenerative disease models. It also previously received support from Parkinson’s UK to investigate POLG activation mechanisms in Parkinson’s disease research. These activities support exploratory investigation but do not establish additional clinical indications for PX578.
Pretzel Therapeutics maintains another programme focused on mitochondrial RNA polymerase, known as POLRMT, for metabolic disease applications. This represents a different target and therapeutic strategy from POLG activation. The existence of both programmes demonstrates a broader interest in mitochondrial biology without making their clinical development prospects interchangeable.
For PX578, expansion into additional indications would depend on target biology, preclinical evidence and an appropriate regulatory development plan. The immediate priority remains establishing whether the compound has acceptable safety and meaningful biological activity in patients with POLG-mediated disease. Broader commercial opportunities should remain secondary to that first clinical test.
What are the commercial and financing implications of moving PX578 towards Phase 2 development?
Pretzel Therapeutics is a privately held biotechnology company headquartered in Waltham, Massachusetts, with research operations in Mölndal, Sweden. Its pipeline is focused on medicines intended to address mitochondrial dysfunction through small-molecule pharmacological mechanisms. PX578 is the company’s lead development asset and its most advanced disclosed programme.
The transition from healthy volunteer research into a controlled Phase 2 patient study represents an important increase in development complexity. The company must coordinate rare disease recruitment, specialist clinical assessments, drug supply and repeated safety monitoring. International trial execution may also introduce additional regulatory and operational requirements.
The October announcement does not disclose the company’s current cash position, financing runway or the budget required to complete POLARIS. Consequently, the financial resources available for subsequent development cannot be assessed reliably from the disclosed information. Any commercial projections would also be premature because PX578 has not demonstrated clinical efficacy or received marketing approval.
The programme may eventually attract partnering interest if its biological rationale is confirmed in patients. However, no licensing or commercial collaboration transaction was announced in connection with the UK authorisation. The value of such an asset would depend heavily on the quality of clinical results, patient population and potential development requirements.
Manufacturing readiness will be another important consideration. A small-molecule product may offer some practical advantages over complex biological therapies, but commercial development still requires robust controls over drug substance, formulation and consistency. The company will need to establish that its production process can support later trials and potential regulatory submissions.
What evidence would demonstrate that PX578 is genuinely modifying POLG disease progression?
The most important evidence will involve whether PX578 produces clinically meaningful changes in the intended patient population. Improvements in mitochondrial DNA levels could provide support for target engagement, but biological markers must be interpreted alongside symptoms and functional outcomes. A medicine may affect a laboratory measurement without necessarily altering the underlying course of disease.
POLARIS will therefore need to generate information about both pharmacological activity and clinical effects. Investigators will examine whether the treatment is tolerated and whether the observed exposure produces relevant biological changes. The controlled design should help distinguish potential treatment effects from background variation.
Longer-term follow-up will eventually be important because POLG-related disorders are generally progressive. Demonstrating a temporary improvement in a biomarker or functional measure would not automatically establish durable disease modification. Subsequent trials may need to assess whether treatment preserves function or reduces clinically consequential deterioration over time.
Safety will also be central to interpretation. Patients with POLG disease may already have neurological, hepatic or muscular complications that affect treatment tolerance. A medicine designed to improve mitochondrial function must demonstrate that the intended pharmacological effect can be achieved without introducing unacceptable risks.
The UK authorisation is an important advance because it allows Pretzel Therapeutics to move towards evaluating PX578 in the patients for whom the medicine is being developed. Its existing preclinical evidence and completed healthy volunteer study provide a scientific foundation, but neither establishes clinical benefit in POLG disease.
The next decisive milestone will be initiation of POLARIS and the generation of controlled patient data. If the study demonstrates target engagement alongside an acceptable safety profile and clinically meaningful outcomes, it could provide a basis for further development. Until those findings are available, PX578 remains a promising but unproven investigational approach to addressing the mitochondrial DNA depletion associated with POLG-mediated disease.
